The substance’s beneficial properties might be due to its ability to reduce inflammation, which has been linked to both Alzheimer’s disease and major depression, according to Dr. Gary Small.
Palexpo, Geneva, Switzerland
May 15-17, 2018
New Research Paper on Theracurmin® was published on Nature.com Scientific Reports
Suppression of NLRP3 Inflammasome Activation Ameliorates Chronic Kidney Disease-Induced Cardiac Fibrosis and Diastolic Dysfunction.
New Research Paper on Theracurmin® was published on Molecular Nutrition & Food Research
Curcumin improves glucose tolerance via stimulation of glucagon-like peptide-1 secretion.
New Research Paper on Theracurmin® was published on International Journal of Chronic Obstructive Pulmonary Disease
Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD.
New Research Paper on Theracurmin® was published on Oncology Reports
Theracurmin® efficiently inhibits the growth of human prostate and bladder cancer cells via induction of apoptotic cell death and cell cycle arrest.
New short review on EMIQ® was published on World Biomedical Frontiers
Flavonoids for Allergic Diseases: Present Evidence and Future Perspective.
Theravalues Corporation participates in
Supply Side West
Mandelay Bay, Las Vegas, NV
October 5-9, 2015
We’re pleased to have actively participated as an exhibitor at one of the United State’s most important trade shows focused on health and nutritional supplements and ingredients.
We found that our innovative products, Theracurmin® Highly Bioavailable Curcumin, and EMIQ® (Enzymatically Modified Isoquercitrin) were enthusiastically received by the attendees. We’ve made many valuable new contacts, and we look forward to interacting with each and every one of them in the future.
At Theravalues Corporation, we’re grateful for this positive response and hope that we will be able to help many more companies who adapt the health benefits of Theracurmin® and EMIQ® in their nutritional supplement products.
Theravalues Corporation delivers presentations at
ISNFF 2015 in Wuxi, China
September 20 -23, 2015
Oral session 20: Curcumin, Resveratrol and Other Bioactives in Focus
– O111. Theracurmin 2: Short-term effects of highly-bioavailable curcumin for treating early and advanced knee osteoarthritis in human
– O112. Clinical application of highly bioavailable curcumin for patients with cancer
– O113. Theracurmin 3. Highly bioavailable curcumin and its development and clinical applicationNOTE: